Genexine's 'GX-188E' Combined with Keytruda Phase 2 Clinical Results Selected for Oral Presentation at ESMO

[Asia Economy Reporter Lee Gwan-joo] Genexine announced on the 25th that the Phase 2 clinical trial results of the combination of the cervical cancer therapeutic DNA vaccine 'GX-188E' and Keytruda have been selected for an oral presentation at the European Society for Medical Oncology (ESMO).

ESMO, held from the 9th to the 13th of next month in Paris, France, is considered one of the largest oncology conferences worldwide, alongside the American Society of Clinical Oncology (ASCO).

The presentation will be delivered by Professor Lee Sung-jong of Seoul St. Mary's Hospital, who participated in the clinical trial. The final Phase 2 results evaluating antitumor response and safety in 60 subjects will be presented to clinicians and multinational pharmaceutical experts attending ESMO, followed by an expert discussion.

GX-188E is a DNA-based therapeutic vaccine that induces antigen-specific T cell immune responses against the oncogenic proteins E6/E7 produced by HPV types 16 and 18, the main causes of cervical cancer, thereby treating the cancer.

Keytruda blocks the interaction between a specific protein (PD-L1) secreted by cancer cells to deactivate human T cells and the immune cell protein (PD-1). When administered in combination with GX-188E, it is expected to facilitate T cell selection and exhibit a higher antitumor effect.

Neil Warma, CEO of Genexine, said, "We are pleased to share very important clinical outcomes regarding Genexine's innovative immuno-oncology therapeutic DNA vaccine and immune checkpoint inhibitor combination therapy through this ESMO oral presentation. Genexine will proceed with the procedures for conditional approval application with the Ministry of Food and Drug Safety after completing this Phase 2 clinical trial."

This content was produced with the assistance of AI translation services.